T2 Biosystems, Inc. reiterated revenue guidance for the year 2024. The Company continues to expect full year 2024 total sepsis and related product revenue of $10.0 million to $11.0 million, representing growth of 49% to 64%, compared to $6.7 million in 2023. The Company?s 2024 revenue guidance consists entirely of sepsis and related product revenue and does not include potential sales of the T2Lyme Panel or the T2Biothreat Panel.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.36 USD | -9.92% |
|
+0.94% | -14.58% |
06-25 | T2 Biosystems Signs Exclusive Distribution Deal for Hong Kong, Macau | MT |
06-25 | T2 Biosystems Announces Commercial Expansion Through Hong Kong and Macau Distributor | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.58% | 102M | |
+5.16% | 212B | |
+9.62% | 188B | |
+31.18% | 157B | |
+33.37% | 114B | |
+3.46% | 64.01B | |
+1.51% | 48.83B | |
-4.27% | 39.3B | |
+0.88% | 35.97B | |
+8.44% | 27B |
- Stock Market
- Equities
- TTOO Stock
- News T2 Biosystems, Inc.
- T2 Biosystems, Inc. Reiterates Revenue Guidance for the Year 2024